TrialClinical pharmacokinetics2014

Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.

Fabrice Balavoine et al.PubMed ↗Publisher ↗

No numbers read from the abstract.